- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
A Closer Look at IL-17 Inhibitors in Psoriasis : Episode 6
Opinion
Video
Safety Considerations for IL-17 Inhibitors
Panelists discuss how IL-17 inhibitors are generally well-tolerated, but common adverse effects include infections, particularly candidiasis, and potential increased suicidal ideation risk. Patients should be informed of candidiasis risk, especially with bimekizumab (Gordon, 2022), and monitored for mood changes, as IL-17s and IL-23s may impact mental health (Blauvelt, 2023). Open discussions help assess risks while ensuring treatment benefits.
Video Player is loading.
Video content above is prompted by the following:
- Now let’s talk about the safety of the IL-17 inhibitor class. What is the overall safety of these agents, and what are some common adverse effects?
- How do you talk to your patients about some of the specific adverse events observed with some of these agents such as infections/candidiasis or increased risk of suicidal ideation?
- Suicidal ideation risk of IL-17s and IL-23s (Blauvelt, 2023)
- Candidiasis recurrence with bimekizumab (Gordon, 2022)
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Selecting and Dosing IL-17 Inhibitors in Psoriasis
Key Takeaways on GEP Testing in Melanoma and SCC
De-Escalating Treatment Plans With Gene Expression Profiling in an 80-Year-Old Man With SCC
Balancing Education and Reassurance: Guiding Parents Through the Safety Profile of New Therapies
Essential Monitoring Considerations for Prescribing Topical JAK Inhibitors in Younger Children
Evaluating the Safety of Topical JAK Inhibitors in the Pediatric Population: Insights into Systemic Risks and Adverse Effects
Safety Considerations in Pediatric Atopic Dermatitis Treatments
Quality of Life Impact: Supporting Patients With GPP
The Challenges of Diagnosis and Management of GPP
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Related Content
